November is Stomach Cancer Awareness Month. Stomach cancer is swift, fatal and the five-year survival rate is tragically low at only 31.2%. Nearly 2,500 Australians will be diagnosed with stomach cancer this year and the disease affects twice as many men as women. The early symptoms, such as bloating, nausea, tiredness or heartburn, can be subtle and easy to ignore.
Watch the Channel 10 News report featuring Gill Worden who lost her husband Tony to stomach cancer, and Professor Niall Tebbutt, a leading GI cancer researcher involved in our cutting-edge INTEGRATE IIa/b clinical trial:
The impact of stomach cancer: Gill, Nadia & Trine’s stories
To help raise awareness and funds for more research, Gill recently shared her and Tony’s story with us, alongside two other incredible women who have tragically lost men they loved to stomach cancer, Trine Kirkegaard Simpson and Nadia De Giuseppe and Gillian Worden. In this video they explain their losses and the impact of stomach cancer on their families.
Our Stomach Cancer Research
The GI Cancer Institute is currently conducting two clinical trials offering new treatments to people with stomach cancer:
- INTEGRATE II/IIb: The purpose of INTEGRATE II is to determine whether a treatment called regorafenib improves overall survival for people with advanced gastro-oesophageal cancer. INTEGRATE IIb will determine whether a combination of regorafenib and the immunotherapy treatment nivolumab is more effective than standard chemotherapy for these patients.
- TOPGEAR: The purpose of TOPGEAR is to investigate whether the addition of chemoradiotherapy treatment to chemotherapy will be better than chemotherapy alone as a treatment for people with stomach cancer before they undergo surgery.
You can change the odds
Any donation, no matter what size, will help us to conduct clinical trials that lead to better health outcomes for people diagnosed with stomach cancer. 100% of your donation will go towards research, and you can select the cancer type your gift will go towards.